LP-352 is under clinical development by Longboard Pharmaceuticals and currently in Phase II for Lennox-Gastaut Syndrome. According to GlobalData, Phase II drugs for Lennox-Gastaut Syndrome have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LP-352’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Longboard Pharmaceuticals overview
Longboard Pharmaceuticals (Longboard) is a clinical-stage biopharmaceutical company that discover and develops novel, transformative medicines for neurological diseases. The company’s pipeline program includes LP352, an oral 5-HT2c super agonist targeting dravet syndrome, lennox-gastaut syndrome (LGS), tuberous sclerosis complex (TSC), CDKL5 deficiency disorder, and other epileptic disorders; LP143, a CB2 agonist against amyotrophic lateral sclerosis (ALS) and neuroinflammatory disorders; and LP659, S1P receptor modulator targeting multiple neuroinflammatory disorders. It is also developing medicines for the treatment of central nervous system neuroinflammatory diseases and epileptic encephalopathies. Longboard is headquartered in La Jolla, California, the US
For a complete picture of LP-352’s drug-specific PTSR and LoA scores, buy the report here.